Moderna
Trade Moderna 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics.
MRNA Key Statistics
Stock Snapshot
With a market cap of 9.76B, Moderna(MRNA) trades at $24.70. The stock has a price-to-earnings ratio of -3.10.
On 2025-11-14, Moderna(MRNA) stock traded between a low of $24.18 and a high of $24.96. Shares are currently priced at $24.70, which is +2.1% above the low and -1.1% below the high.
Moderna(MRNA) shares are trading with a volume of 3.61M, against a daily average of 12.23M.
During the past year, Moderna(MRNA) stock moved between $23.04 at its lowest and $48.92 at its peak.
During the past year, Moderna(MRNA) stock moved between $23.04 at its lowest and $48.92 at its peak.
MRNA News
Moderna (MRNA) retained its spot as the most shorted S&P 500 (SP500) stock as a percentage of float in October, followed by Charter Communications (CHTR) and Th...
Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions AI Analyst can help you make smarter investment...
Mixed options sentiment in Moderna (MRNA), with shares down $1.15 near $25.56. Options volume running well above average with 49k contracts traded and calls lea...
Analyst ratings
59%
of 27 ratingsMore MRNA News
Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the February 2026 expiration. One of the key inputs that goes into the price...
In the past week, Moderna reported third quarter financial results showing a year-over-year revenue decrease to US$1.02 billion and a net loss of US$200 million...
Telemark Asset Management, LLC established a new position in Moderna (MRNA 1.71%), acquiring 500,000 shares valued at approximately $12.91 million as of Septemb...
Moderna, Inc. (MRNA) is a biotechnology firm based in Cambridge, Massachusetts, that focuses on mRNA technology to create innovative medicines and vaccines. The...
Analyst Courtney Breen of Bernstein maintained a Hold rating on Moderna, retaining the price target of $25.00. Meet Your ETF AI Analyst Discover how TipRanks' E...
Tim Anderson, an analyst from Bank of America Securities, reiterated the Sell rating on Moderna. The associated price target was lowered to $21.00. Meet Your ET...